(123rf.com Image)
Charleston, South Carolina-based Afaxys, Inc., a Public Benefit Corporation and health-care company focused on serving public health professionals and their patients, announced the retirement of Ronda Dean, chief executive officer and co-founder effective Jan. 2, 2026.
At that time, Christian Bloomgren, current president and chief commercial officer (CCO), will assume the role of president and CEO, and Dean will serve as his executive advisor.
"Serving as CEO and president of Afaxys for the past 17 years has been an incredible privilege," Dean said. "From the very beginning, our mission has been grounded in reproductive justice and gender equity, and I am profoundly grateful to my colleagues, partners, and customers who have shared that passion and purpose with me."
Of Bloomgren, Dean added, "He is an exceptional leader with strong strategic insights that will allow Afaxys to carry forward its legacy and shape a strong future for the company."
Bloomgren brings more than 25 years of experience in pharmaceutical, biotech, diagnostics, and medical devices, with strong expertise in women's health.
In his current role as president and CCO, Bloomgren leads the strategy and execution of marketing, sales, and growth initiatives.
Said Bloomgren: "As we move forward, my priority is to stay true to our mission, while positioning the company to achieve even greater growth and impact as leaders in public health."
"On behalf of the Board, I want to thank Ronda for her transformative leadership in co-founding Afaxys and her incredible contributions to our mission and success over the years," added Sarah Stoesz, chair of the Board of Afaxys. "The selection of Ronda's successor has been an important objective for the Board over the past few years, and we are equally excited to welcome Christian as our new CEO."
Afaxys partners with public health and private industry to ensure health-care professionals have stable pricing and reliable access to the products and services they need to care for their patients.
The Afaxys enterprise comprises a family of companies that operate under three wholly owned subsidiaries: Afaxys Pharma, LLC, Afaxys Drug Development, LLC and Afaxys Group Services, LLC (AGS).
Afaxys Pharma provides a broad portfolio of branded and generic contraceptives to the public health-care market.
Afaxys Drug Development provides development and regulatory services of pharmaceutical products with a focus on rapid and efficient launch readiness to promote Afaxys' strategic goal of cost-conscious product commercialization.
AGS is a strategic sourcing operation that negotiates favorable pricing across a broad base of products and services through its Group Purchasing Organization.
The Medical University of South Carolina (MUSC) Board of Trustees approves the appointment of Aaron D. Howell, CPA, MBA, as executive vice president of finance and operations. Read More »
Comments
No comments on this item Please log in to comment by clicking here